INS and diabetes mellitus: While GSK126 is not licensed for diabetic mellitus the primary findings add to previous clinical reports demonstrating superior transcriptional reactivation by restoring histone content.18 Whether GSK126 treatment of exocrine cells restores the content of other histone modifications such as acetylation associated with the human insulin chromatin domain is unclear.